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Th  e development of positron emission tomography 
(PET) amyloid imaging radiotracers has allowed the in 
vivo measurement of ﬁ  brillar β-amyloid (Aβ) throughout 
the brain. Amyloid imaging is contributing to the early 
detec  tion of pathology and diagnosis of Alzheimer’s 
disease (AD), to the selection and therapeutic monitoring 
of patients in clinical trials, and to diﬀ  erential diagnosis 
among dementia subtypes. In addition, it is enhancing 
our understanding of the role of Aβ in the temporal 
course of disease by allowing prospective assessment of 
early pathological changes and the cognitive correlates of 
these changes in Aβ deposition. PET imaging of ﬁ  brillar 
Aβ provides many opportunities for early diagnosis of 
cognitive impairment and the understanding of disease 
progression, but the prediction of clinical outcomes in 
cognitively unimpaired individuals remains challenging.
Th   e large percentage of individuals who have sub  stan-
tial levels of Aβ but remain cognitively normal is a 
potential limitation in the use of amyloid imaging for 
prediction of clinical outcomes. Th   irty to ﬁ  fty percent of 
individuals who are clinically normal at death have 
suﬃ     cient Aβ plaques at autopsy to meet pathological 
criteria for AD [1,2]. Similarly, PET imaging studies also 
show that about 30% [3-7] of cognitively normal indivi-
duals have varying levels of increased Aβ on imaging. 
Some investigators argue that cognitively normal indi-
viduals with AD pathology are in a preclinical stage of 
AD [8-10]. However, we [11] and others [12] have shown 
that antemortem cognitive change in this group of 
‘asympto  matic AD’ individuals does not diﬀ  er  signiﬁ  -
cantly from cognitively normal individuals without AD 
pathology at autopsy, in contrast to the marked memory 
decline evident in those who develop subsequent cog-
nitive impairment (Figure 1a).
Th   e challenge posed by these asymptomatic AD 
individuals in the application of PET Aβ imaging for 
clinical diagnosis has led some to question whether these 
tools will be useful in prediction of clinical outcomes. 
Individuals with elevated Aβ on PET imaging may not 
have passed fully through the risk period for AD and 
represent a heterogeneous group, with some at increased 
risk for cognitive impairment and others likely to remain 
healthy (as represented by the autopsy-deﬁ  ned asympto-
matic AD group). In this paper, we suggest ways in which 
informa  tion from PET amyloid imaging can be used in 
combina  tion with cognitive change to improve the utility 
of these measures for prediction of cognitive decline and 
impair  ment and to identify factors that promote cogni-
tive resilience in the presence of Aβ pathology. We ﬁ  rst 
review current evidence demonstrating diﬀ  erences  in 
imaging-assessed Aβ burden among groups of AD, mild 
cognitive impairment (MCI) [13], and cognitively normal 
(CN) individuals. Next, we review cross-sectional and 
longitudinal studies of associations between Aβ deposi-
tion and cognitive performance. Finally, we conclude 
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© 2011 BioMed Central Ltdwith a discussion of what amyloid imaging in conjunction 
with cognitive performance can and cannot tell us about 
prediction of cognitive impairment and resilience. We 
highlight how information from imaging and neuro-
psychological assessments can be used in combination to 
improve prediction of clinical outcomes and to enhance 
our understanding of the cognitive correlates of Aβ 
deposition and progression.
Amyloid imaging in cognitive impairment and in 
healthy older adults
Imaging with the radioligand [11C]Pittsburgh Compound-
B (PiB) has provided strong evidence of group diﬀ  erences 
between cognitively impaired (AD and MCI) and normal 
(CN) older adults in global as well as regional measures 
of Aβ deposition (for review, see [14]). It is noteworthy 
that the level of Aβ in MCI individuals who are PiB-
positive approaches the level in AD, suggesting either a 
plateau [15] or a low rate [16] of Aβ accumulation after 
the appearance of clinical symptoms. Frontal, lateral 
temporal, and parietal regions show consistent patterns 
of elevated Aβ in those with cognitive impairment 
compared with healthy older adults, with more variable 
ﬁ  ndings with respect to group diﬀ  erences in the occipital 
and striatal regions (for review, see [14]). Th  ese global 
and regional patterns of diﬀ  erences between impaired 
and CN individuals are generally consistent across a 
variety of PET amyloid radiotracers. Th  e majority of 
studies to date have used PiB, but a number of 
[18F]  radiotracers for amyloid imaging recently have 
become available and have been applied in imaging 
studies of AD. Th   ese include Florbetaben (BAY94-9172), 
Flutemetamol (GE067) and Florbetapir (AV-45), and all 
show diﬀ  erences between AD patients and controls that 
are similar in distribution to group diﬀ  erences using PiB 
[17-19]. Additional studies are required to provide infor-
mation on long-term predictive utility of these amyloid 
imaging tracers, especially in the case of MCI and 
preclinical AD in asymptomatic individuals. However, 
the availability of [18F] ligands, which have a 110-minute 
half-life and can be produced for regional distribution, 
will allow more widespread research and potential 
clinical applications compared to [11C] ligands, which 
have a 20-minute half-life requiring on-site radiopharma-
ceutical production.
Another PET radiotracer that has been used to evaluate 
AD pathology is [18F]FDDNP. [18F]FDDNP diﬀ  ers from 
the other amyloid imaging compounds in several ways. It 
labels plaques and tangles, as well as alpha-synuclein 
[20]. Furthermore, the radioactivity signal from this tracer 
is lower than the signal achieved with more speciﬁ  c Aβ 
radiotracers, leading to diﬃ   culties in quantiﬁ  cation [21]. 
However, an interesting application of this tracer is the 
potential use of subtraction measures to highlight non-
amyloid pathology [22]. By using multiple radiotracers, 
[18F]FDDNP shows additional binding in the hippo-
campal formation compared to PiB, perhaps reﬂ  ecting 
neuroﬁ  brillary tangle pathology [22].
Despite consistent group diﬀ  erences between impaired 
and CN individuals, amyloid imaging compounds show 
varying levels of elevated Aβ across individuals. In 
studies with PiB, attempts have been made to deﬁ  ne 
values for a PiB positive study indicating elevated Aβ 
burden. A variety of cut-points have been used (for 
Figure 1. Longitudinal trajectories of verbal memory performance as a function of amyloid pathology. (a) Autopsy studies. (b) In vivo 
[11C]Pittsburgh Compound-B (PiB) imaging studies. (a) Reproduced with premission from Driscoll and colleagues [11], showing similar longitudinal 
trajectories of verbal memory performance (z-scores of free recall on the Cued Selective Reminding Test) in normal individuals with and without 
Alzheimer’s disease (AD) pathology in contrast to marked decline in individuals who later are diagnosed with MCI or AD. (b) Adapted with 
permission from Resnick and colleagues [6] and shows diff  erences in longitudinal trajectories of verbal memory performance (total immediate free 
recall on the California Verbal Learning Test) as a function of PiB retention. Note that individuals in the autopsy study are older than those in the 
imaging studies and are more likely to have passed through the risk period for cognitive impairment. MCI, mild cognitive impairment.
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method used for quantiﬁ  cation - for example, standard 
uptake value ratio (SUVR) versus dynamic modeling of the 
time course of radioactivity in brain. Both cut-points and 
approaches that examine Aβ as a continuous measure have 
been used to determine relationships with cognitive status.
Amyloid imaging may be especially useful in distin-
guishing between individuals with MCI who will progress 
to dementia and AD versus those who will not progress 
to dementia [23-25]. MCI represents a heterogeneous 
group, with individuals showing either AD-like levels of 
Aβ deposition or CN-like levels of Aβ deposition [25-28]. 
Approximately one-half of individuals with amnestic 
MCI [25,29], characterized by memory impairment, have 
elevated Aβ on imaging and have an increased risk of 
conversion to AD (see below). MCI individuals without 
elevated Aβ have a lower likelihood of progression to AD 
[24,25]. Th   ese individuals may be cases of misdiagnosis, 
may have diﬀ   erent conditions that interfere with 
cognitive function, or may be false nega  tives on imaging 
due to the fact that current radiotracers do not label all 
Aβ isoforms [30].
Variability in imaging-assessed amyloid burden is also 
apparent in older cognitively healthy adults. As noted 
above, the proportion of PiB-positive individuals has 
ranged from 20% in a study by Mintun and colleagues [5] 
to 47% in the multicenter study performed through the 
Alzheimer’s Disease Neuroimaging Initiative [4]. Cogni-
tively healthy PiB-positive individuals show a range of 
values of PiB that are clearly detectable on imaging but 
are typically below those observed in AD. To date, the 
primary factors associated with increased Aβ burden in 
CN individuals are older age and Apolipoprotein E 
(APOE) ε4 genotype [7,31]. For example, in the Australian 
Imaging, Biomarker, and Lifestyle (AIBL) study of 177 
healthy controls, 33% of healthy controls were PiB-
positive, with a rate of 65% in individuals older than 
80 years compared with 18% in individuals aged 60 to 
69 years [7,31]. Moreover, the rate of elevated PiB binding 
was more than double in APOE ε4 gene carriers (49%) 
compared with noncarriers (21%) [7]. Cognitively healthy 
individuals with elevated amyloid burden likely represent 
a heterogeneous group with respect to long-term 
outcome. While some of these individuals will progress 
to cognitive impairment and AD, others will remain 
resilient in the face of pathology. Th  e latter group may 
parallel the group we have called asymptomatic AD at 
autopsy (and others have called high pathology controls 
or preclinical AD), because they do not show accelerated 
cognitive decline despite substantial amyloid pathology 
[11]. Some investigators attribute this resilience to 
‘cognitive reserve’ [32-34], implying greater neural 
complexity or plasticity at baseline, but the resilience may 
also reﬂ  ect a more general capacity to regain homeostasis 
across body systems in the face of a variety of age-
associated insults, including Aβ deposition.
Amyloid imaging and cognitive performance
Investigations of the associations between in vivo 
measure  ment of amyloid burden and cognition are 
neces  sary to determine the extent and conditions under 
which elevated amyloid burden is associated with 
cognitive decline. When data are combined across groups 
of individuals with AD, MCI and CN older adults, higher 
Aβ burden is correlated with lower episodic memory 
performance [21,28,35,36]. Th  ese associations are also 
evident in analyses pooling MCI and AD together [37] 
and in studies pooling CN and AD together [33,38]. 
Correlations between Aβ burden and performance in 
non-memory cognitive domains also have been identiﬁ  ed 
in analyses pooling groups of impaired and unimpaired 
individuals [33,38]. In one study, correlations across 
diagnostic groups suggested that increased frontal PiB is 
associated with lower memory whereas increased 
parietal PiB is associated with lower performance on 
non-memory functions [36].
Associations between in vivo neuropathology and cogni-
tive performance across combined groups of impaired and 
unimpaired individuals also have been reported using 
[18F]FDDNP as the radiotracer [20,39]. In addition to 
inverse associations between [18F]FDDNP binding and 
verbal paired associate memory when CN and MCI 
individuals were combined, [18F]FDDNP was also inversely 
associated with performance on other cognitive measures, 
including mental status and digit recall, across all groups 
[20]. Spatial associations of [18F]FDDNP binding with 
lower performance on tests of episodic memory and 
frontal lobe function across groups localized to entorhinal, 
lateral temporal, parietal, orbitofrontal and dorsolateral 
prefrontal cortex [39]. Mesial temporal associations with 
[18F]FDDNP may reﬂ   ect sensitivity to neuroﬁ  brillary 
tangles in these regions.
Although associations between PET imaging measures 
of neuropathology and memory performance are evident 
in analyses combining impaired and unimpaired indivi-
duals, relationships with memory performance within a 
diagnostic group are more complex (Tables 1 and 2). As 
summarized in Table 1, the correlations between cross-
sectional measures of Aβ burden using PiB and cognitive 
performance in AD patients tend to be absent to weak 
[28,35,37,40]. In MCI, some but not all studies indicate 
that higher Aβ burden is associated with lower perfor-
mance on tests of episodic memory [35,37,41]. A recent 
study from a larger cohort of 57 MCI participants from 
the AIBL study on aging showed only a trend to a 
relationship between higher neocortical Aβ burden and 
lower long delay free recall performance on the California 
Verbal Learning Test, a measure of verbal memory [7].
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are even more variable in studies of CN individuals. 
Table 2 summarizes ﬁ  ndings from cross-sectional studies 
of CN older adults. Several investigations have shown 
negative cross-sectional correlations between PiB reten-
tion and measures of episodic memory [19,41,42], and 
one study indicated that cognitive reserve, measured by 
the National Adult Reading Test, may modify this 
association [33]. However, the largest study of 177 CN 
adults found no signiﬁ  cant cross-sectional correlations 
with episodic memory [7], suggesting that a few PiB-
posi  tive individuals may have a large inﬂ  uence on ﬁ  nd-
ings in smaller samples. Th   e varied results across studies 
highlight the complexity of the relationship between 
cognitive performance and amyloid deposition at the 
earliest stages of cognitive decline.
Th   e few longitudinal investigations of cognitive change 
in relation to Aβ burden have more consistently shown 
associations for cognitively healthy individuals (Table 2). 
For example, Villemagne and colleagues [43] reported 
that greater decline in word list recall was associated with 
higher Aβ deposition in nondemented elderly who 
ultimately progressed to MCI/AD but not in individuals 
who remained cognitively normal [43]. Storandt and 
colleagues [42] found that elevated Aβ burden was 
associated with greater longitudinal decline in episodic 
and working memory, as well as visuospatial ability, and 
we [6] reported that higher Aβ was associated with 
greater longitudinal decline in verbal memory (Figure 1b), 
executive function and mental status, but not visual 
memory. Our observations of signiﬁ  cant  relationships 
between higher PiB retention and greater cognitive 
decline in cognitively healthy individuals appear at ﬁ  rst 
glance to conﬂ  ict with our autopsy ﬁ  ndings [11] showing 
similar longitudinal cognitive trajectories in older adults 
with and without AD pathology (Figure 1a,b). However, 
participants in imaging studies are younger and have not 
passed fully through the risk period for cognitive decline. 
Th   us, cognitively healthy individuals with elevated Aβ on 
imaging include those who are in a preclinical phase of 
AD as well as those who will be resilient and maintain 
cognitive health.
Amyloid imaging and cognition in prediction of 
Alzheimer’s disease
Th   ere are two ways that amyloid imaging may be useful 
in combination with cognition in prediction of the 
likelihood of developing AD. Th  e ﬁ   rst involves using 
amyloid imaging to distinguish among mildly impaired 
individuals to predict who is likely to progress and who is 
more likely to remain stable. Table 3 describes the results 
of initial attempts to use amyloid imaging in predicting 
outcomes in MCI. Th  e second application combines 
information on longitudinal cognitive decline with Aβ 
status to determine which cognitively healthy individuals 
are at highest risk for progression to impairment and AD.
Table 1. Cross-sectional associations between PiB-assessed β-amyloid burden and cognition in AD and MCI
     Number  of  Mean   
Study Year  Samplea subjectsa  age (SD)  Method  Associations between PiB retention and cognitive function
Furst et al. [40]  2010  AD  39  68.3 (10.5)  DVR  No association with MMSE or CDR-SOB
Forsberg et al. [37]  2010  AD  37  67.5 (9.2)  SUVR  Higher PiB in bilateral frontal cortices and posterior cingulate gyrus weakly 
            associated with lower verbal memory (RAVLT) in AD alone
Grimmer et al. [54]  2009  AD with   32  66.9 (8.5)  SUVR  Higher PiB in bilateral frontal and anterior cingulate cortex, and lentiform
    AD-typical         nucleus (P ≤ 0.05) associated with higher CDR-SOB
   FDG  scan
Rowe et al. [28]  2007  AD  17  74.0 (11.3)  DVR  No signifi  cant association with long delay verbal recall (CVLT) or MMSE
Pike et al. [35]  2007  AD  31  74.8 (10.2)  SUVR  No association with composite score of episodic memory 
Rowe et al. [7]  2010  MCI  57  75.5 (7.5)  SUVR  Higher PiB shows trend with lower long delay verbal recall (CVLT; r = -0.24, 
           P = 0.07)
Wolk et al. [25]  2009  MCI  26  70.2 (8.8)  DVR  PiB-positive aMCI have lower verbal delayed recall than PiB-negative aMCI 
           ( P < 0.01) but PiB-positive were also substantially older
Lowe et al. [29]  2009  MCI  23  82 (aMCI-),   SUVR  No signifi  cant memory diff  erence between aMCI-negative and 
        73 (aMCI+)    aMCI-positive (but aMCI-negative substantially older)
Mormino et al. [41]  2009  PiB+ MCI  39  75.0 (7.9)  DVR  Higher PiB associated with lower verbal delayed recall (RAVLT; P = 0.05)
Forsberg et al. [23]  2008  MCI  21  63.3 (7.8)  SUVR  Higher PiB in posterior cingulate, frontal, and temporal cortex (P ≤ 0.05) 
            associated with lower composite score of episodic memory 
Pike et al. [35]  2007  MCI  33  70.7(9.6)  SUVR  Higher PiB associated with lower composite score of episodic memory 
            (r = -0.6, P < 0.001) and remains signifi  cant when limited to aMCI
aIn some cases a study subsample. AD, Alzheimer’s disease; aMCI, amnestic MCI; CDR-SOB, Clinical Dementia Rating scale Sum of Boxes; CVLT, California Verbal 
Learning Test; DVR, distribution volume ratio; FDG, fl  uorodeoxyglucose; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; PiB, [11C]Pittsburgh 
Compound-B; RAVLT, Rey Auditory Verbal Learning Test; SD, standard deviation; SUVR, standard uptake value ratio. 
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helpful in distinguishing between individuals who will 
convert to AD and those who will remain stable [23-25] 
or develop other forms of dementia. Rates of conversion 
to AD in MCI individuals with a positive amyloid imaging 
scan are substantially higher than those with a negative 
PiB scan, with the latter showing less than 10% rates of 
conversion over 3 years [24,25]. As described in Table 3, 
MCI converters may also have diﬀ  erent patterns of PiB 
amyloid deposition compared to MCI non-converters 
[24], with higher PiB retention in posterior cingulate 
[23,44] and frontal [44] regions. Okello and colleagues 
[24] identiﬁ  ed a subset of PiB-positive MCI individuals 
who rapidly progressed to AD. Compared to PiB-positive 
slower MCI converters and nonconverters, the rapid 
converters had higher PiB retention in anterior cingulate, 
frontal, and lateral temporal cortices. In addition, the 
presence of the APOE ε4 allele in PiB-positive MCI 
individuals was associated with higher rates of conversion 
to AD [24].
In CN adults, consideration of Aβ burden alone showed 
that risk for AD in PiB-positive individuals was 4.8 times 
that in PiB-negative CN individuals over a 2.4-year 
follow-up [45] (Table 3). However, no studies to date have 
combined PET measures of Aβ burden with cognitive 
performance for prediction of AD risk in CN individuals. 
In our concluding comments, we operationalize the way 
that cognitive performance, especially on episodic memory 
tests, can be used in combination with Aβ burden to 
further increase prediction of CN individuals who are 
likely to develop AD versus remain healthy.
Conclusion
Th  e ability to image brain Aβ in vivo is advancing our 
understanding of the neurobiology of cognitive impair-
ment and holds promise as a tool that will contribute to 
Table 2. Associations between β-amyloid burden and cognition in cognitively normal individuals 
        Number of  Mean    Associations between amyloid imaging and
Study Year  Radiotracer  Samplea subjectsa  age (SD)  Method  cognitive function
Cross-sectional measures of concurrent β-amyloid load and cognition
Rowe et al. [7]  2010  PiB   CN  177  71.6 (7.4)  SUVR  No association with long delay verbal recall (CVLT)
          No  diff  erence in long delay verbal recall between those with high 
          versus  low  PiB  binding
Rentz et al. [33]  2010  PiB   CN  66  73.9 (8.1)  DVR  No main eff  ect of precuneus PiB on cognitive function
              Higher precuneus PiB associated with lower cued (but not free 
              recall) and canonical variate score in CN individuals with low but 
              not high cognitive reserve measured by AMNART
Storandt et al. [42]  2009  PiB   CN  135  PiB- 74.3 (6.2)  BP  No association with global, verbal, spatial, or working memory
          Pib+ 75.4 (6.3)     composites or individual cognitive measures
Braskie et al. [39]  2010  [18F]FDDNP  CN  10  73 (10.4)  DVR  Higher [18F]FDDNP in right frontal and some parietal areas 
              associated with lower composite cognitive score 
Mormino et al. [41]  2009  PiB   CNb  20  72.3 (6.0)  SUVR, DVR  Higher PiB associated with lower episodic memory composite 
          score  (P < 0.01) 
Mormino et al. [41]  2009  PiB   CNc  17  78.5 (5.4)  SUVR, DVR  No associations with episodic memory composite score
Rowe et al. [28]  2007  PiB   CN  27  72.6 (6.9)  DVR  No diff  erence in cognitive performance between PiB-positive and 
          PiB-negative
Pike et al. [35]  2007  PiB   CN  32  71.7 (6.6)  SUVR  Higher PiB associated with lower episodic memory composite 
          score  (r  =  -0.38,  P < 0.05)
              PiB-positive compared with PiB-negative had lower episodic 
          memory  composite  score  (P < 0.05)
Cross-sectional measures of β-amyloid load and longitudinal measures of cognition
Resnick et al. [6]  2010  PiB   CN  57   78.8 (6.2)  DVR  Higher PiB associated with greater decline in immediate and
        (6 CDR = 0.5)       delayed verbal recall and MMSE (all P ≤ 0.01) but not visual 
          memory
              Associations most pronounced for frontal and lateral temporal 
              cortex, as well as putamen
Storandt et al. [42]  2009  PiB   CN  135  PiB- 74.3 (6.2)  BP  Higher PiB associated with greater decline in working memory
          Pib+ 75.4 (6.3)     and visuospatial ability 
Villemagne et al. [43]  2008  PiB   Stable (S),   24 S,   S 71.7 (6.7)  SUVR  Higher PiB associated with greater decline in word-list recall
      declining (D)  10 D  D 75.5 (4.4)    (r = -0.78) in decliners only 
aIn some cases a study subsample. bBerkeley Aging Study. cAlzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. AMNART, American National Adult Reading Test; 
BP, binding potential; CDR, Clinical Dementia Rating scale; CN, cognitively normal; CVLT, California Verbal Learning Test; DVR, distribution volume ratio; MMSE, Mini-
Mental State Examination; PiB, [11C]Pittsburgh Compound-B; RAVLT, Rey Auditory Verbal Learning Test; SD, standard deviation; SUVR, standard uptake value ratio.
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tion of who will ultimately develop AD and who will 
maintain cognitive health. From a number of studies, it is 
clear that PET amyloid imaging shows robust diﬀ  erences 
in Aβ levels among groups of AD, MCI and CN 
individuals. When groups are combined, associations 
between higher Aβ and lower cognitive performance, 
especially episodic memory, emerge consistently across 
studies. Within diagnostic groups, correlations between 
Aβ burden and cognitive performance are less clear in 
cross-sectional investigations (summarized in Tables 1 
and 2). Th   e few longitudinal studies to date that included 
measures of change in cognitive performance over time 
provide more convincing evidence that increased Aβ 
correlates with greater decline in verbal memory, and 
perhaps other cognitive measures, such as executive 
function and mental status.
Th   e potential utility of Aβ imaging as a clinical tool for 
early diagnosis of preclinical AD remains limited by its 
lower speciﬁ   city due to the high proportion of PiB-
positive CN individuals [3,5,28,31,35]. Additional chal-
lenges in interpreting a positive amyloid scan are the 
presence of amyloid plaques in other forms of dementia, 
for example, Lewy body disease [28], and the fact that Aβ 
also binds to intravascular amyloid, as is the case with 
cerebral amyloid angiopathogy [46]. Further, current 
radiotracers for Aβ imaging label predominantly ﬁ  brillar 
Aβ and do not measure soluble forms, providing only a 
partial quantiﬁ   cation of Aβ burden. Despite these 
limitations, Aβ imaging in combination with information 
on cognitive function can help inform early detection 
and diagnosis of AD.
Th  e ways in which joint consideration of Aβ imaging 
and cognitive function may help inform prediction of AD 
and cognitive health are illustrated in Table 4. Th  is 
simpliﬁ  ed table shows that, in the presence of cognitive 
impairment, Aβ imaging will help distinguish between 
Aβ-positive individuals with MCI who are likely to 
progress to AD versus Aβ-negative individuals with MCI 
who have a much lower risk of progression. Aβ-negative 
individuals with apparent cognitive impairment may be 
misdiagnosed as MCI and convert back to normal, may 
have a diﬀ   erent neurodegenerative disorder or other 
condi  tion, or may be false negative Aβ cases due to a 
diﬀ  erent isoform [30]. Similarly, Aβ imaging may help 
distinguish between CN individuals with longitudinal 
decline in memory who are likely to develop AD versus 
those whose memory decline may be associated with 
other factors, such as other medical conditions or 
medications. Whereas Aβ-positive CN individuals with 
memory decline greater than expected for age are at 
increased risk for AD, memory declines in older adults 
who are Aβ-negative are more likely attributable to other 
factors. Finally, CN individuals who are Aβ-negative and 
do not show accelerated longitudinal decline in memory 
can be reassured that they are not likely to develop AD 
over the next several years. CN individuals who are Aβ-
positive and have stable longitudinal memory 
Table 3. Amyloid imaging and prediction of conversion to Alzheimer’s disease
       Number  of  Mean   
Study Year  Radiotracer  Samplea   subjectsa age  (SD)  Method  Findings
Okello et al. [24]  2009  PiB   MCI  31  69.4  SUVR  82% PiB-positive MCI convert to AD compared to 7% of 
         (7.9)    PiB-negative  MCI
              47% PiB-positive MCI who convert to AD within 1 year have 
              higher PiB in anterior cingulate and frontal cortex (P < 0.05),
              APOE ε4 is associated with faster conversion rates in 
              PiB-positive MCI (P < 0.05) 
Wolk et al. [25]  2009  PiB   MCI  26 (23 with   70.2  DVR  38% PiB-positive MCI but no PiB- convert to AD over 22 months
       follow-up)  (8.8)
Morris et al. [45]  2009  PiB   CN  159  71.5  BP  Higher PiB retention predicts progression from CDR 0 to MCI 
          (8.6)    (hazard ratio = 2.74) and AD (hazard ratio = 4.85) over mean 
             2.4  years
Koivunen et al. [44]  2008  PiB   aMCI  15  71.1  SUVR,  Elevated PiB in six converters in posterior cingulate and frontal 
          (7.2)  DVR  cortex as well as elevated neocortical score 
Forsberg et al. [23]  2008  PiB   MCI  21  63.3  SUVR  Higher PiB retention in frontal, parietal, and temporal cortices 
         (7.8)    (P < 0.01) in MCI converters than CN individuals
              Higher PiB retention in posterior cingulate gyrus in MCI 
              converters than MCI nonconverters (P < 0.01)
             No  diff  erence in PiB retention between MCI converters and AD 
Small et al. [20]  2006  [18F]FDDNP  AD, MCI,   4 MCI,   NA for this  DVR  Three disease progressors had increases in [18F]FDDNP between 
      CN  8 CN  subset    5.5% to 11.2% compared to ≤3% in nine non-progressors 
aIn some cases a study subsample. AD, Alzheimer’s disease; aMCI, amnestic MCI; APOE, Apolipoprotein E; BP, binding potential; CN, cognitively normal; DVR, 
distribution volume ratio; MCI, mild cognitive impairment; NA, not available; PiB, [11C]Pittsburgh Compound-B; SD, standard deviation; SUVR, standard uptake value 
ratio.
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AD or may not have reached a threshold of pathology 
where memory decline is evident. Th  ese ﬁ  ndings,  of 
course, must be interpreted in the context of an 
individual’s age and APOE genotype, as younger CN 
individuals with Aβ pathology may not have passed 
through the risk period for accelerated cognitive decline 
and dementia. Longi  tudinal follow-up studies will 
determine the time course of the development of Aβ and 
whether there truly are individuals who are resilient to 
pathology or in whom the clinical symptoms are delayed. 
Moreover, comparisons between Aβ-positive individuals 
who have stable memory performance and those who 
show cognitive decline and impairment may lead to 
identiﬁ  cation of factors that promote cognitive resilience 
despite pathology. Th  e ability to stratify longitudinal 
trajectories of memory performance by Aβ will also 
inform and perhaps revise our deﬁ   nition of what 
constitutes ‘normal aging’ in the absence of pathology. 
Finally, prediction models incor  por  ating other factors, 
such as APOE genotype, cere  bro  spinal ﬂ  uid (CSF) Aβ 
and Tau, as well as both regional and network-based 
spatial measures of brain atrophy on MRI [47] may 
increase sensitivity and speciﬁ  city for early identiﬁ  cation 
of AD and cognitive resilience.
In addition to its contributing role in early identiﬁ  cation 
of individuals at greatest risk for AD, amyloid imaging is 
also aiding in drug development and elucidating the 
regional distribution and temporal course of the neuro-
biological changes leading to memory loss and AD. 
Amyloid imaging informs the selection of participants in 
therapeutic trials - for example, for anti-Aβ treatments - 
and may be useful in monitoring therapeutic response. In 
one recent trial, an 8.5% decline in Aβ level was detected 
in response to an anti-Aβ treatment [48]. PET amyloid 
imaging is also being used in combination with CSF and 
MRI measures to track the temporal course and regional 
brain changes preceding memory loss. Amyloid deposi-
tion is hypothesized to be an early stage of the disease 
process, with functional and structural brain changes, 
including hippocampal volume loss, occurring closer to 
the manifestation of clinical symptoms [49]. Imaging 
tools provide information throughout the brain, directing 
attention to the regions showing the earliest amyloid 
deposition and volumetric changes. In some cases, such 
as early amyloid deposition in precuneus/posterior 
cingu  late, these imaging ﬁ   ndings are focusing more 
detailed investigation on brain regions that were not 
included previously in laborious neuropathological 
evalu  a  tions [50,51]. Amyloid imaging also provides the 
oppor  tunity for prospective assessment of amyloid 
deposi  tion in relation to changes in cognitive perfor-
mance and regional brain volumes [47,52]. Th   e ability to 
track pathology over time using both amyloid imaging 
and CSF measures of Aβ [53] will enhance understanding 
of the temporal sequence of events in parallel and subse-
quent to amyloid deposition. Such studies may reveal 
whether there is some threshold beyond which memory 
impairment is evident and may identify factors that either 
render some individuals with substantial pathology 
resilient to disease or promote a delayed onset of clinical 
symptoms.
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